Joshua E Allen

This inventor holds 24 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Cancer Therapy. Top assignees: Oncoceutics, Inc., The Penn State Research Foundation, Other. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joshua E Allen. Retrieved from https://idiyas.com/inventor/joshua-e-allen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 2.4

ph-index = 6

Forward Citations = 59(Granted Patents)

Location History:

Hershey, PA (US) (2014 - 2016)
Philadelphia, PA (US) (2016 - 2017)
Ann Arbor, MI (US) (2017 - 2019)
Cambridge, MA (US) (2017 - 2024)
New Haven, CT (US) (2019 - 2024)

Company Filing History:

The Penn State Research Foundation

patents

2 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Imipridones

TRAIL Gene Induction

G Protein-Coupled Receptor

Gliomas

Combination Therapy

Small Molecules

Tumor Cells

Cancer Treatment

Therapeutics

Hexahydroimidazo

Pyrimidin

Analog Salts

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12102639 - Imipridones for gliomas (2024-10-01),

2. 12036223 - Small molecule trail gene induction by normal and tumor cells as an anticancer therapy (2024-07-16),

3. 11976068 - 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy (2024-05-07),

4. 11116771 - G protein-coupled receptor (GPCR) modulation by imipridones (2021-09-14),

5. 10953014 - 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy (2021-03-23),

6. 10946022 - Imipridones for gliomas (2021-03-16),

7. 10456402 - 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy (2019-10-29),

8. 10369154 - Imipridones for gliomas (2019-08-06),

9. 10366681 - Integrated lug and drum mount (2019-07-30),

10. 10266533 - 7-Benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy (2019-04-23),

11. 10172862 - Imipridones for gliomas (2019-01-08),

12. 10045992 - 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy (2018-08-14),

13. 9845324 - 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy (2017-12-19),

14. 9792888 - Drum mount (2017-10-17),

15. 9688679 - 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy (2017-06-27),

Title: **Innovative Contributions of Joshua E. Allen in Cancer Treatment**

Introduction

Joshua E. Allen, a distinguished inventor based in New Haven, CT, has significantly impacted the field of cancer treatment through his innovative work. With a remarkable portfolio of 20 patents, his research primarily focuses on novel therapeutic methods targeting complex conditions such as gliomas.

Latest Patents

Among his latest patents is the development of Imipridones for gliomas. This innovation involves selectively modulating Class A G protein-coupled receptors (GPCRs), specifically the D2-like subfamily of dopamine receptors, which are pivotal in addressing cancers, including midline gliomas characterized by histone H3 mutations. His patent outlines methods for determining the responsiveness of subjects to treatment regimens, as well as assessing the effectiveness of such therapies through imipridone administration.

Another noteworthy patent attributed to Allen pertains to the compound 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one. This patent describes methods for utilizing this compound, its analogs, and pharmaceutically acceptable salts in therapeutic treatments, particularly for cancer, effectively broadening the scope of available treatment options for patients.

Career Highlights

Joshua E. Allen has lent his expertise to esteemed organizations, including Oncoceutics, Inc. and The Penn State Research Foundation. His contributions to these institutions underline his commitment to advancing cancer research and developing innovative therapies that can potentially transform treatment outcomes for patients.

Collaborations

Throughout his career, Allen has collaborated with notable figures in the field, such as Martin Stogniew and Wafik S. El-Deiry. These collaborations have enriched his research endeavors, fostering an environment conducive to innovation and advancement in cancer therapeutics.

Conclusion

Joshua E. Allen stands out as a visionary inventor whose patents facilitate significant progress in cancer treatment. His innovative contributions redefine therapeutic possibilities, exemplifying the profound impact that dedicated inventors can have in the realm of medicine.

Profile summary based on public USPTO records.